Within the thyroid follicular lumen, it combines with tyrosine residues on thyroglobulin under the catalysis of thyroid peroxidase (TPO), ultimately converting into biologically active T3 and T4 ( While these epidemiological observations establish a clear association between iodine exposure and AITD risk, a deeper mechanistic understanding is required to elucidate the causal pathways involved
suitable for daily use by healthy adults
CYP1A1 metabolism of estrogen, polyaromatic hydrocarbons, and more CYP1A2 metabolism of caffeine, duloxetine, bupropion, aflatoxin B, and more CYP2A6 metabolism of nicotine, coumarin, and more CYP2B6 metabolism of ketamine, methadone, sertraline, and more CYP2C9 metabolism of warfarin, rosuvastatin, celecoxib, and more CYP2C19 metabolism of clopidogrel, some proton pump inhibitors, more CYP2D6 metabolism of some antidepressants, antipsychotics, more CYP3A4 metabolism of half of all prescription drugs CYP2E1 metabolism of fatty acids, alcohol, and some anesthetics Phase II detoxification genes: UGT, GST, Nrf2 Phase II detoxification involves taking the metabolites of phase I and modifying them to be easily excreted through conjugation with sulfur, glutathione, glucuronic acid, amino acids, or methyl groups
Gradual improvement is usually noticed with consistent daily use